Oxford COVID-19 Vaccine: Here's What You Need To Know

COVID-19 vaccine developed by the Oxford University and drug maker AstraZeneca has received green light. The vaccine gives us new hope of beginning the end of the pandemic in the New Year 2021.

The authorization in the UK recommended two //doses administered with an interval of between four and 12 weeks.

Nearly 21 Percent US Adults Not Planning to Get Covid Vaccine: Survey
As the US prepares its nationwide vaccination program, a new survey has revealed that at least 21.3 percent of adults in the country are not planning to get the coronavirus vaccine shot.

‘Prime Minister Narendra Modi visited the Serum Institute of India (SII). The company has a stockpile 40-50 million doses of its COVID-19 vaccine and India is likely to receive majority of these 50 million doses.’

Tweet it Now

This regimen was shown in clinical trials to be safe and effective at preventing symptomatic COVID-19, with no severe cases and no hospitalisations more than 14 days after the second dose, according to AstraZeneca.

Now known as COVID-19 Vaccine AstraZeneca, it was formerly called AZD1222.

AZD1222 was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein.

COVID Vaccine: Moderna Coronavirus Vaccine All Set For FDA Emergency Approval
A high powered vaccine advisory panel has endorsed Moderna's COVID-19 vaccine for emergency use approval (EUA) by the FDA.

After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

As announced on November 23, the primary efficacy endpoint based on a pooled analysis showed that the vaccine was 70.4 percent effective at preventing symptomatic COVID-19 occurring more than 14 days after receiving two doses of the vaccine.

No COVID Vaccine Approval Yet, Drug Regulator Analysing SII and Bharat Biotech Data
Analysis of the additional data and information submitted by Bharat Biotech and Serum Institute of India (SII) is still being conducted by the regulator Central Drug Standard Control Organisation's (CDSCO) Subject Expert Committee.

A secondary efficacy endpoint of prevention of severe disease demonstrated no cases of severe infections or hospitalizations in the vaccine group.

In addition to the programme led by Oxford University, AstraZeneca is conducting a large trial in the US and globally.

Side Effects, Efficacy Reasons for COVID Vaccine Hesitancy in India: Study
Even as the Central government preps up to roll out the COVID-19 vaccination drive soon, about 60 percent of people are hesitant to take it due to the fear of side effects, efficacy, and reduction in cases, according to a new study.

Serum Institute of India (SII), the world's largest vaccine manufacturer by volume, is manufacturing a version of the Oxford-AstraZeneca COVID-19 vaccine "Covishield" in India.

Prime Minister Narendra Modi visited the Pune-based company on November 28 to review vaccine development.

The company this week said that it has a stockpile 40-50 million doses of its COVID-19 vaccine.

India is likely to receive majority of these 50 million doses.

"We have 40-50 million doses of Covishield stockpiled. Once we get regulatory approvals in a few days, it will be down to the government to decide how much they can take and how fast. We will be producing around 300 million doses by July 2021," Serum Institute CEO Adar Poonawalla recently said in a press conference.

The company applied for emergency authorisation of the vaccine in India in December.

It is expected that this vaccine will play a major role in India's plan to vaccinate its population against COVID-19 due to several factors including low-cost, ease of storage and transport.

Source-IANS